These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15299077)

  • 21. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
    Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
    Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Suppression of insulin receptor substrate 1 (IRS-1) promotes mammary tumor metastasis.
    Ma Z; Gibson SL; Byrne MA; Zhang J; White MF; Shaw LM
    Mol Cell Biol; 2006 Dec; 26(24):9338-51. PubMed ID: 17030605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer.
    Denzel MS; Hebbard LW; Shostak G; Shapiro L; Cardiff RD; Ranscht B
    Clin Cancer Res; 2009 May; 15(10):3256-64. PubMed ID: 19447866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multistep mouse mammary tumorigenesis through pre-neoplasia to neoplasia and acquisition of metastatic potential.
    Tsubura A; Yoshizawa K; Uehara N; Yuri T; Matsuoka Y
    Med Mol Morphol; 2007 Mar; 40(1):9-17. PubMed ID: 17384984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Premalignant and malignant mammary lesions induced by MMTV and chemical carcinogens.
    Medina D
    J Mammary Gland Biol Neoplasia; 2008 Sep; 13(3):271-7. PubMed ID: 18663563
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ.
    Namba R; Young LJ; Maglione JE; McGoldrick ET; Liu S; Wurz GT; DeGregorio MW; Borowsky AD; MacLeod CL; Cardiff RD; Gregg JP
    Breast Cancer Res; 2005; 7(6):R881-9. PubMed ID: 16280035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PAK1 hyperactivation is sufficient for mammary gland tumor formation.
    Wang RA; Zhang H; Balasenthil S; Medina D; Kumar R
    Oncogene; 2006 May; 25(20):2931-6. PubMed ID: 16331248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transgenic expression of polyomavirus middle T antigen in the mouse prostate gives rise to carcinoma.
    Lee SH; Jia S; Zhu Y; Utermark T; Signoretti S; Loda M; Schaffhausen B; Roberts TM
    J Virol; 2011 Jun; 85(11):5581-92. PubMed ID: 21411524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptoralpha expression during tumor progression.
    Yoshidome K; Shibata MA; Couldrey C; Korach KS; Green JE
    Cancer Res; 2000 Dec; 60(24):6901-10. PubMed ID: 11156389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
    Aprelikova O; Tomlinson CC; Hoenerhoff M; Hixon JA; Durum SK; Qiu TH; He S; Burkett S; Liu ZY; Swanson SM; Green JE
    PLoS One; 2016; 11(5):e0155262. PubMed ID: 27171183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.
    Masumori N; Thomas TZ; Chaurand P; Case T; Paul M; Kasper S; Caprioli RM; Tsukamoto T; Shappell SB; Matusik RJ
    Cancer Res; 2001 Mar; 61(5):2239-49. PubMed ID: 11280793
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype.
    Podsypanina K; Li Y; Varmus HE
    BMC Med; 2004 Jun; 2():24. PubMed ID: 15198801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo positron-emission tomography imaging of progression and transformation in a mouse model of mammary neoplasia.
    Abbey CK; Borowsky AD; McGoldrick ET; Gregg JP; Maglione JE; Cardiff RD; Cherry SR
    Proc Natl Acad Sci U S A; 2004 Aug; 101(31):11438-43. PubMed ID: 15277673
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis.
    Wang A; Arantes S; Yan L; Kiguchi K; McArthur MJ; Sahin A; Thames HD; Aldaz CM; Macleod MC
    BMC Cancer; 2008 Sep; 8():268. PubMed ID: 18808719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Jnk2 effects on tumor development, genetic instability and replicative stress in an oncogene-driven mouse mammary tumor model.
    Chen P; O'Neal JF; Ebelt ND; Cantrell MA; Mitra S; Nasrazadani A; Vandenbroek TL; Heasley LE; Van Den Berg CL
    PLoS One; 2010 May; 5(5):e10443. PubMed ID: 20454618
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The C3(1)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma.
    Green JE; Shibata MA; Yoshidome K; Liu ML; Jorcyk C; Anver MR; Wigginton J; Wiltrout R; Shibata E; Kaczmarczyk S; Wang W; Liu ZY; Calvo A; Couldrey C
    Oncogene; 2000 Feb; 19(8):1020-7. PubMed ID: 10713685
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transgenic mice reveal roles for TGFalpha and EGF receptor in mammary gland development and neoplasia.
    Schroeder JA; Lee DC
    J Mammary Gland Biol Neoplasia; 1997 Apr; 2(2):119-29. PubMed ID: 10882298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis.
    Forrester E; Chytil A; Bierie B; Aakre M; Gorska AE; Sharif-Afshar AR; Muller WJ; Moses HL
    Cancer Res; 2005 Mar; 65(6):2296-302. PubMed ID: 15781643
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic interaction of transforming growth factor alpha and c-myc in mouse mammary and salivary gland tumorigenesis.
    Amundadottir LT; Johnson MD; Merlino G; Smith GH; Dickson RB
    Cell Growth Differ; 1995 Jun; 6(6):737-48. PubMed ID: 7669729
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2-targeted therapy reduces incidence and progression of midlife mammary tumors in female murine mammary tumor virus huHER2-transgenic mice.
    Finkle D; Quan ZR; Asghari V; Kloss J; Ghaboosi N; Mai E; Wong WL; Hollingshead P; Schwall R; Koeppen H; Erickson S
    Clin Cancer Res; 2004 Apr; 10(7):2499-511. PubMed ID: 15073130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.